Acadia Healthcare Forms Joint Venture Partnership with SolutionHealth in New Hampshire

Healthcare company Acadia, Inc. announced that it has formed a joint venture with SolutionHealth to build a state-of-the-art, 144-bed behavioral health hospital in southeastern New Hampshire to address growing and unmet need. for accessible, high-quality behavioral health services in the state. This partnership expands Acadia’s acute services reach to a new state with a world-class healthcare system.The hospital will provide a full range of continuum behavioral health services to inpatients, including the most vulnerable members of the community. This project will be supported by a $15 million public grant from the New Hampshire Department of Health and Human Services to cover the capital costs of building the new hospital. The new hospital represents Acadia’s 19th joint venture partnership. Joint ventures remain the main strategic growth driver of the Company.
“This partnership will bring critically needed behavioral healthcare services to southeast New Hampshire,”
“As we have proven in our other 18 joint ventures, we will bring the best practices of both organizations to develop and operate quality behavioral healthcare services, providing healing and hope to those in need in the surrounding communities. We will continue to partner with leading health systems to expand access to mental healthcare and substance use treatment programs across our country.”
Chris Hunter, Chief Executive Officer of Acadia Healthcare.
“This joint venture is fully supported by the Boards of Trustees and Executive Leadership across our system as it expands our ability to provide expert care to an ever-expanding facet of the communities we serve,”
“The goals of the joint venture include increasing behavioral health access in the region, reducing emergency department waiting periods for behavioral health triage and disposition, and providing a state-of-the-art behavioral health environment center of excellence for patients, close to home.”
SolutionHealth Chief Executive Officer, Bradley Kreick.
Next Post

Amneal Launches Authorized Generic for Xyrem® (sodium oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Pharmaceuticals, Inc. announced the launch of its authorized generic for Xyrem®1 oral solution CIII in the United States. Sodium Oxybate oral solution, 0.5 g/mL is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with […]